Lupin Q1 FY27 Results: Revenue up 32%, PAT up 16% consolidated

Revenue growth above 20%Profit growth above 25%Results View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹2385.00

prior close

₹2410.00

announcement price

After-mkt

timing

Nifty Midcap 150market+0.2%-0.8% vs market

Pharmaceuticals peers, median of 167sector+0.3%-0.9% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.9

10m

-1.4

15m

-1.0

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.2-0.8+0.3-0.9

Next day

-3.6+0.7-4.3+0.7-4.3

-4.4+0.6-5.1+0.6-5.1

-5.1+0.9-6.0+0.5-5.6

-5.6+1.0-6.6+1.2-6.9

-6.3+0.5-6.8+0.2-6.5

-6.4+0.2-6.6+0.2-6.6

15d

-8.7+0.8-9.6+1.4-10.1

-11.8-1.1-10.7+2.4-14.2

-15.0-6.3-8.7+1.8-16.8

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin posted Q1 FY27 standalone revenue of Rs 71,719 million, up 25.6% YoY, with net profit of Rs 27,146 million, up 27.6% YoY. Consolidated revenue grew 32% to Rs 82,769 million and PAT rose 16% to Rs 14,170 million. New acquisition VISUfarma (Euro 192.8 million) consolidated from April 2026. Limited review by Deloitte Haskins & Sells; prior period results were reviewed by a different auditor.

Likely market impact

Strong top-line growth and improved standalone profits. European acquisition expands footprint. Auditor change noted; watch litigation and margin trends.